Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | EDNRA | P25101 | 1/20 | 0.75 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.75 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904141 | 0.89 | LMNA (0.79) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL8044673 | 0.89 | LMNA (0.79) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL11153426 | 0.89 | LMNA (0.82) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL10028900 | 0.88 | LMNA (0.81) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL12665451 | 0.86 | LMNA (0.75) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL14176522 | 0.86 | LMNA (0.69) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL11080390 | 0.86 | LMNA (0.78) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL29384458 | 0.86 | LMNA (1.00) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL33963 | 0.86 | LMNA (1.00) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL2635855 | 0.86 | LMNA (1.00) | LMNACYP2C9ATP6V1B2TBXA2REDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| CN-110551124-B | Quinolone compound or agriculturally and pharmaceutically acceptable salt thereof, and preparation method and application thereof | 山东省联合农药工业有限公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-110551124-A | quinolone compound or agriculturally and pharmaceutically acceptable salt thereof, and preparation method and application thereof | SHANDONG UNITED PESTICIDE IND CO LTD | 2019-12-10 | — | — | CN | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746116-B2 | Antibiotic resistance breakers | ABCC1, ARL1, AKR1C3 | LMNA 270/4885CYP2C9 427/4885ATP6V1B2 4866/4885 |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | LMNA 3474/4885CYP2C9 633/4885ATP6V1B2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.